華魯恆升(600426.SH):碳酸二甲酯增產提質系列技改項目投產
格隆匯10月8日丨華魯恆升(600426.SH)公佈,公司碳酸二甲酯增產提質系列技改項目近日實施完畢,產品產量和質量得到大幅提升。
碳酸二甲酯為公司生產乙二醇的衍生產品,公司通過中試實驗,自主研發了乙二醇生產線聯產碳酸二甲酯的新工藝和新型催化技術,產品質量和收率大幅提升。為豐富產品結構,提高整體盈利能力,在完成中試實驗的基礎上,公司對年產50萬噸乙二醇生產裝置實施了增產提質系列技術改造。隨着技改項目陸續完成並投產,預計整套裝置具備聯產30萬噸/年優質碳酸二甲酯的能力。
根據技改項目立項報吿,碳酸二甲酯增產提質系列技改項目總計投資3.2億元,項目建設資金由公司自有資金解決。
碳酸二甲酯增產提質系列技改項目陸續投入達產後,將進一步豐富公司產品結構,增強應對市場變化的能力,提升公司盈利水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.